Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

ShedRx vs Tell Her Doc

Two GLP-1 desks, one scoreboard. We put ShedRx and Tell Her Doc head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →
vs
No. 190 · Grade C

Tell Her Doc

Visit Tell Her Doc Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 67 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make Tell Her Doc a bad call — it's best for readers who want women-focused compounded semaglutide or tirzepatide in injection, oral or odt form with a named pharmacy. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
86
34
Supply Reliability
86
71
Transparency
84
80
Access Breadth
85
86
Clinical Oversight
85
76
Track Record
86
65
ShedRxBrief Score 87 · 67Tell Her Doc

Price, coverage & the tracker

ShedRxTell Her Doc
Brief Score87/100 (B+)67/100 (C)
Semaglutide$199/moFrom $269/mo (plus a separate fee, compounded)
Tirzepatide$299/moNot disclosed
CoverageNot disclosedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerFallingprice fallingNewnew to the tracker, no prior reading

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

Tell Her Doc: New to the tracker on 1 August 2026. The published line reads From $269/mo (plus a separate fee, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.